Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inhaled IBIO123 for Post-exposure Prophylaxis of COVID-19
NCT05639166Phase 2Completed
- Sponsor
- Immune Biosolutions
- Start
- Feb 2023
- Primary completion
- May 2023
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
Phase 2, randomised, double-blind trial of IBIO123 in coronavirus disease 2019 (COVID-19), sponsored by Immune Biosolutions. Primary endpoint: Laboratory-confirmed COVID-19 infections at Day 14. Started Feb 2023; status: completed.
02
Drugs
IBIO123
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT05639166.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05639166.